Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/32962
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRey, Enrique
dc.contributor.authorMearin, Fermín
dc.contributor.authorAlcedo, Javier
dc.contributor.authorCiriza, Constanza
dc.contributor.authorDelgado-Aros, Silvia
dc.contributor.authorFreitas, Teresa
dc.contributor.authorMascarenhas, Miguel
dc.contributor.authorMínguez, Miguel
dc.contributor.authorSantos, Javier
dc.contributor.authorSerra, Jordi
dc.date.accessioned2019-06-28T17:11:44Z-
dc.date.available2019-06-28T17:11:44Z-
dc.date.issued2017
dc.identifier.citationAdv Ther.2017 03;(34)3:587-598
dc.identifier.urihttps://hdl.handle.net/20.500.12530/32962-
dc.description.abstractIrritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic or recurrent abdominal pain in association with defecation or a change in bowel habits. A predominant disorder of bowel habits, IBS is classified into three main subtypes: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D) and IBS alternating between constipation and diarrhea (IBS-M). Linaclotide is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GC-CA) that is licensed for the symptomatic treatment of moderate-to-severe IBS-C in adults. This review aims to facilitate and optimize clinical practices, establishing common guidelines to monitor patients with IBS-C that are treated with linaclotide.
dc.language.isoeng
dc.rightsopenAccess-
dc.subjectAbdominal pain
dc.subjectBloating
dc.subjectConstipation
dc.subjectConstipation-predominant irritable bowel syndrome
dc.subjectGastroenterology
dc.subjectLinaclotide
dc.subjectPatient management
dc.subjectRecommendations
dc.subject.meshGastrointestinal Agents
dc.subject.meshHumans
dc.subject.meshPeptides
dc.subject.meshReceptors, Atrial Natriuretic Factor
dc.subject.meshTreatment Outcome
dc.subject.meshConstipation
dc.subject.meshIrritable Bowel Syndrome
dc.titleOptimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.
dc.typeArtículo
dc.identifier.pubmedID28083815
dc.format.volume34
dc.format.page587-598
dc.identifier.e-issn1865-8652
dc.identifier.journalAdvances in therapy
dc.identifier.doi10.1007/s12325-016-0473-8
dc.format.number3
dc.identifier.pmcPMC5350198
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
Appears in Collections:Hospitales > H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos

Files in This Item:
File Description SizeFormat 
PMC5350198.pdf494.38 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.